Immunotherapies targeting the programmed death-1 (PD-1)/PD ligand 1 (PD-L1) axis yielded promising results for patients with NSCLC, and several studies suggest that PD-L1 expression may predict the response to this type of immunotherapy12,13. The gene discussed is CD274; the disease is non-small cell lung carcinoma.